Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Monday, May 8, 2023
The use of RPMI 8226 cellular membrane lipid-extracted nanoliposomes may prove to be more effective than standard nanoliposome extractions in the treatment of patients with multiple myeloma, according to a presentation given at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract 2004/18). Drug-loaded cellular membrane lipid-extracted nanoliposomes in vitro should be the primary focus of future investigative efforts to determine their efficacy in this patient population, suggested Matthew Amorin, PharmD, of the Massachusetts College of Pharmacy and Health Sciences, Worcester, and colleagues.
The RPMI 8826 cell line was used as the model for multiple myeloma and was compared with the Y79 retinoblastoma control cell line. Cell lines were exposed overnight to two separate liposome preparations loaded with 3 mol% doxorubicin hydrochloride (DOX), a multiple myeloma–targeted cellular membrane lipid-extracted nanoliposomes preparation of 95% dioleoyl phosphocholine (DOPC) and 5 mol% RPMI 8826 cell lipid extract (LE), and a nonspecific liposome 100% DOPC preparation. After exposure, a cytotoxicity assay was used to measure extracellular lactate dehydrogenase (LDH) activity.
The study authors reported a 203-nm and 235-nm mean diameter size for the DOX-loaded DOPC and DOPC/LE, respectively. In addition, doxorubicin incorporation was 72% in the DOPC preparation and 84% in the DOPC/LE preparation. After being exposed to RPMI 8826, rates of cytotoxicity were significantly improved in the DOPC/LE preparation compared with the DOX preparation. Moreover, increased extracellular LDH activity was observed in the DOPC/LE preparation. However, no significant differences in cytotoxicity or LDH activity were observed between the DOX preparation and the Y79 control sample.
Disclosure: The study authors reported no conflicts of interest.
JNCCN Spotlights
